Adamas Pharma (ADMS) – Business Wire
-
Adamas Announces New Employment Inducement Grants
-
Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards
-
Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society’s (MDS) Congress
-
Adamas Announces New Employment Inducement Grants
-
Adamas to Present at Upcoming September Investor Conferences
-
Adamas Announces New Employment Inducement Grant
-
Adamas Reports Second Quarter 2021 Financial Results
-
Adamas to Announce Second Quarter Financial Results and Host Conference Call on August 9, 2021
-
Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101
-
Adamas Announces New Employment Inducement Grant
-
Adamas to Present at Upcoming William Blair Biotech Focus Conference
-
Adamas to Present at Upcoming SVB Leerink CNS Forum
-
Adamas Announces New Employment Inducement Grant
-
New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson’s Disease
-
Adamas to Present at Upcoming June Conferences
-
Adamas Reports First Quarter 2021 Financial Results
-
Adamas Announces New Employment Inducement Grant
-
Adamas to Present at Upcoming BofA Conference
-
Adamas Launches “Picture More Time” Campaign to Raise Awareness and Understanding of the Impact of OFF Time and Dyskinesia for People With Parkinson’s Disease and Care Partners
-
Adamas to Announce First Quarter Financial Results and Host Conference Call on May 10, 2021
-
Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson’s disease presented at American Academy of Neurology (AAN) Annual Meeting
-
Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting
-
Adamas to Present at Upcoming Needham Conference
-
Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinson’s disease
-
Adamas Announces New Employment Inducement Grant
-
Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering
-
Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering
-
Adamas Reports Fourth Quarter and Full Year 2020 Financial Results
-
Adamas to Present at Upcoming Healthcare Conferences
-
Adamas to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call on February 23, 2021
-
Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes
-
Adamas Announces Settlement of Patent Litigation with Zydus
-
E-Scape Bio Appoints Anthony Rimac as Chief Financial Officer and Ann Kapoun, Ph.D., as SVP of R&D
Back to ADMS Stock Lookup